Atlas Venture Associates IX’s Cogent Biosciences COGT Stock Holding History

Atlas Venture Associates IX’s Portfolio COGT Stock Details COGT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-466,832	Closed	-$4.21M	–	7
2022 Q2	$4.21M	Sell	466,832 -450,000	-49%	-$3.07M	9.57%	3
2022 Q1	$6.87M	Hold	916,832	–	–	6.32%	4
2021 Q4	$7.87M	Hold	916,832	–	–	3.43%	4
2021 Q3	$7.71M	Hold	916,832	–	–	2.56%	6
2021 Q2	$7.44M	Hold	916,832	–	–	1.31%	6
2021 Q1	$8.05M	Buy	916,832 +636	+0.1%	+$6.12K	1.35%	6
2020 Q4	$10.3M	Buy	916,196 +75,812	+9%	+$833K	1.63%	5
2020 Q3	$7.87M	Hold	840,384	–	–	8.14%	4
2020 Q2	$1.55M	Hold	840,384	–	–	1.65%	6
2020 Q1	$1.38M	Hold	840,384	–	–	2.91%	6
2019 Q4	$2.42M	Hold	840,384	–	–	4.22%	6
2019 Q3	$4.84M	Hold	840,384	–	–	7.97%	5
2019 Q2	$8.81M	Hold	840,384	–	–	9.42%	5
2019 Q1	$14.8M	Hold	840,384	–	–	13.86%	5
2018 Q4	$14.8M	Hold	840,384	–	–	17.03%	4
2018 Q3	$34.6M	Hold	840,384	–	–	18.33%	4
2018 Q2	$48.2M	Hold	840,384	–	–	21.23%	3
2018 Q1	$37.3M	Buy	+840,384	New	+$37.3M	28.23%	2

Other funds holding COGT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

Atlas Venture Associates IX's COGT Position: Q3 2022 in Review

Atlas Venture Associates IX sold out of Cogent Biosciences (COGT) in Q3 2022, closing a stake of 466,832 shares — an estimated $4.21M sold.

Atlas Venture Associates IX first reported a position in COGT in Q1 2018 and held it in 18 quarters. The position peaked at $48.2M in Q2 2018. 134 funds tracked by Wall St. Rank hold COGT as of Q3 2022.

Atlas Venture Associates IX reported no remaining Cogent Biosciences position as of Q3 2022 after selling out during the quarter.
Atlas Venture Associates IX sold 466,832 Cogent Biosciences shares in Q3 2022, an estimated $4.21M.
Atlas Venture Associates IX first reported a position in Cogent Biosciences in Q1 2018 and held it in 18 quarters.
Atlas Venture Associates IX's Cogent Biosciences position peaked at $48.2M in Q2 2018.
134 funds tracked by Wall St. Rank held Cogent Biosciences as of Q3 2022.

Based on Atlas Venture Associates IX's 13F filing for Q3 2022, filed 10 Nov 2022.